Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics Inc (IKT) is a clinical-stage pharmaceutical company pioneering protein kinase inhibitors for neurodegenerative disorders, including Parkinson's disease. This page serves as the definitive source for official announcements, clinical trial updates, and strategic developments from the company.
Investors and researchers will find curated updates on drug pipeline progress, regulatory milestones, and scientific advancements. Our collection includes earnings reports, partnership announcements, preclinical study results, and FDA correspondence related to candidates like Risvodetinib (IkT-148009) and IkT-001Pro.
All content is rigorously verified to ensure compliance with financial disclosure standards. Bookmark this page for real-time updates on:
• Clinical trial phases for Parkinson's-focused therapies
• Regulatory filings and agency interactions
• Peer-reviewed research publications
• Strategic collaborations in neurodegenerative research
For stakeholders tracking kinase inhibitor development and neurodegenerative treatment innovation, this resource provides essential updates directly from Inhibikase Therapeutics' corporate communications.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that CEO Dr. Milton Werner will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation is scheduled for September 13 at 7:00 AM ET. A webcast will be available on Inhibikase's website for on-demand viewing, with an archived replay accessible for 30 days post-event. Inhibikase focuses on developing therapeutics for Parkinson's disease and related conditions, including their lead program IkT-148009, which has completed Phase 1 studies and is underway in Phase 1b trials.
Inhibikase Therapeutics (Nasdaq: IKT) reported a net loss of $2.6 million for Q2 2021, compared to $0.4 million in Q2 2020. R&D expenses surged to $2.4 million, driven by clinical trial costs. The company initiated a Phase 1b study for IkT-148009, aimed at treating Parkinson's disease, and plans to submit 13-week toxicology studies to the FDA. They also expect to file an IND for IkT-001Pro for Chronic Myeloid Leukemia in Q3 2021. Cash reserves stand at $46.8 million, expected to fund operations until mid-2023.
Inhibikase Therapeutics (Nasdaq: IKT) announced FDA clearance for a Phase 1b extension study of IkT-148009, a drug targeting Parkinson's disease, after positive safety and tolerability results from a Phase 1 trial in healthy volunteers. This next phase will evaluate the drug's effects on Parkinson's patients, following promising outcomes in preclinical studies. With no significant adverse events reported among 42 subjects in the initial trial, the company aims to advance its therapeutic pipeline, addressing a disease affecting over 1 million individuals in the U.S.
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) announced the closure of its public offering of 15 million shares at $3.00 each, raising gross proceeds of $45 million. This funding aims to support a Phase 1b extension study for IkT-148009 targeting Parkinson's disease, production for upcoming clinical trials, and general R&D activities. The underwriters also have a 45-day option to purchase an additional 2.25 million shares. The offering was registered with the SEC and the final prospectus is available online.
Inhibikase Therapeutics (Nasdaq: IKT) announced a public offering of 15 million shares at $3.00 each, totaling approximately $45 million in gross proceeds. The offering will close on June 18, 2021, subject to customary conditions. Proceeds will fund a Phase 1b extension study for IkT-148009 in Parkinson's patients, production for subsequent studies, and general R&D efforts. The underwriters have a 45-day option to purchase an additional 2.25 million shares. The offering is registered with the SEC under Form S-1.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that CEO Dr. Milton Werner will present at two upcoming virtual healthcare conferences. The first is the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:30 PM ET, followed by the LD Micro Virtual Invitational XI on June 10, 2021, at 11:30 AM ET. Dr. Werner will discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the company's leading treatment for Parkinson's disease. Webcasts will be available for on-demand viewing on the company's website for 30 days after each event.
Inhibikase Therapeutics (Nasdaq: IKT) reported Q1 2021 financial results, highlighting key developments in its Parkinson's disease treatment programs. The company accelerated the Phase 1 study of IkT-148009, aiming for regulatory approval to begin patient dosing by Q3 2021. Toxicology studies for IkT-148009 are ongoing, with an IND application for IkT-001Pro planned for submission in Q3 2021. Financially, Inhibikase reported a net loss of $2.6 million, up from $0.5 million in Q1 2020, with R&D expenses rising to $2.4 million due to clinical trial costs. Cash reserves stood at $9.6 million.
Inhibikase Therapeutics (NASDAQ: IKT) announced that CEO Milton Werner, Ph.D., will present at the Sachs 4th Annual Neuroscience Innovation Forum from April 28-30, 2021. He will discuss clinical measures related to IKT-148009, a treatment for Parkinson's disease, focusing on dosing pharmacokinetics and its mechanism of action. Dr. Werner will also partake in a panel discussion on Parkinson's and Movement Disorders on April 28 at 1:20 p.m. ET. The company is developing therapeutics for Parkinson's and related disorders, currently conducting Phase I studies on IKT-148009.
Inhibikase Therapeutics (IKT) reported financial results for Q4 and the full year 2020, noting a net loss of $1.21 million in Q4, improving from $0.43 million in Q4 2019. For the full year, the net loss was $2.85 million, down from $5.72 million in 2019. The company completed its IPO in December 2020, raising approximately $14.60 million. In early 2021, it commenced patient dosing for IkT-148009, aimed at treating Parkinson's disease, and initiated chronic toxicology studies. Cash reserves stood at $13.95 million as of year-end 2020, supporting ongoing research initiatives.
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) announced that CEO Milton Werner, Ph.D., will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference on March 9, 2021. This online presentation can be accessed in the Investors section of their website starting at 7:00 am ET. The webcast will be available for approximately 90 days post-event. Inhibikase focuses on developing therapeutics for Parkinson's disease, with its lead program IkT-148009 currently in Phase I trials assessing its safety and pharmacokinetics.
